Exicure Rises Following Burixafor Trial Results in Multiple Myeloma
Positive Phase 2 Data: Exicure Inc. shares surged over 65% after presenting favorable phase 2 trial results for Burixafor, an investigational drug for multiple myeloma, at the ASH Annual Meeting.
Trial Results: The trial showed that 89.5% of participants successfully collected the required number of CD34+ cells for transplantation, with rapid mobilization kinetics observed, allowing for same-day administration and apheresis.
Multiple Myeloma Overview: Multiple myeloma is a rare blood cancer affecting plasma cells in the bone marrow, leading to complications like weakened immunity and bone damage, with autologous hematopoietic cell transplantation being a standard treatment.
Comparison with Existing Treatments: Burixafor demonstrated quicker mobilization compared to current FDA-approved CXCR4 antagonists, which require overnight pre-treatment, potentially improving the efficiency of stem cell collection for patients.
Get Free Real-Time Notifications for Any Stock
Analyst Views on XCUR
About XCUR
About the author
Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
- Research Presentation: Exicure will showcase data from its open-label, multicenter Phase 2 trial at the ASTCT meeting from February 4-7, 2026, highlighting the application of burixafor in autologous hematopoietic cell transplantation for multiple myeloma patients, achieving an impressive 89.7% success rate for the primary endpoint, demonstrating both efficacy and safety of the therapy.
- Therapeutic Innovation: The study indicates that the combination of burixafor with propranolol and G-CSF effectively mobilizes hematopoietic progenitor cells, addressing mobilization challenges faced by multiple myeloma patients, particularly in the context of lenalidomide and daratumumab treatment.
- Clinical Application Potential: By blocking CXCR4, burixafor is expected to enhance stem cell mobilization for conditions like multiple myeloma and sickle cell disease, providing a reliable collection strategy for patients who may encounter barriers to successful stem cell collection.
- Future Research Plans: Exicure is also planning a chemosensitization trial in acute myeloid leukemia, leveraging burixafor's ability to mobilize malignant cells from protective bone marrow niches to improve chemotherapy effectiveness, further expanding its therapeutic potential in hematologic diseases.
Exicure Stock Rises 41% Following Positive Phase 2 Results for Multiple Myeloma Treatment
Stock Surge: Exicure, Inc. (XCUR) shares rose 41.37% to $7.45 following positive topline results from its Phase 2 study of burixafor for multiple myeloma.
Efficacy and Safety Signals: The study indicated promising efficacy and safety, boosting investor confidence in burixafor as a potential new treatment for this challenging cancer.
Increased Trading Volume: Trading volume significantly increased as the market reacted to the favorable study results, indicating heightened investor interest.
Stock Volatility: The stock's 52-week range is between $3.20 and $9.80, highlighting the volatility often seen in early-stage biotech companies.
